How much of the $100 million authorization has already been used?

Approximately $17.9 million has been utilized under the program, leaving $82.1 million available for future repurchases. The filing does not break down the timing or execution of these prior repurchases.

What does Caris Life Sciences do with the shares it repurchases?

The filing does not explicitly state the intended use. Share repurchases typically reduce share count, potentially increasing earnings per share, and can return capital to remaining shareholders. Repurchased shares may also be held in treasury for other corporate purposes.

Does the filing specify how these shares will be repurchased?

No. The filing does not disclose whether repurchases will be executed as open-market purchases under Rule 10b-18, via an accelerated share repurchase (ASR) agreement, or through a 10b5-1 trading plan.

Why is Caris announcing a buyback now?

The company reported record Q2 results, including 45% revenue growth and positive free cash flow of $6.4 million for the quarter. Strong operational performance and positive cash generation provide the financial foundation to return capital to shareholders through repurchases.

How does this buyback compare to Caris's market capitalization?

The $100 million authorization represents approximately 0.35% of the company's market capitalization based on its ~282.6 million outstanding shares as of June 30, 2026. The relative size is modest compared to the company's total equity value.

CAI 8-K Filed 2026-08-05 New authorization

Caris Life Sciences authorizes $100M share repurchase program

Biotech firm announces buyback as Q2 revenue surges 45%; $82.1M remains available for repurchase

Authorization$100M

Remaining$82M

MechanismNot specified

What the filing says

Caris Life Sciences announced a share repurchase program of up to $100 million, with approximately $82.1 million remaining available for repurchase under the existing Board authorization, according to its second-quarter 2026 earnings report filed via 8-K on August 5, 2026. The announcement comes as the company reported record operating performance, including total revenue of $263.7 million, a 45% increase year-over-year, and positive Adjusted EBITDA of $55.7 million for the quarter ended June 30, 2026.

The buyback was disclosed in the company's earnings highlights but does not specify the execution mechanism, timeline, or any prior repurchases completed under this authorization. The filing notes that approximately $17.9 million has been utilized under the program, leaving $82.1 million available. The company generated positive free cash flow of $6.4 million in the second quarter and $28.9 million in the first half of 2026, providing financial flexibility for capital allocation.

Execution mechanism was not specified in this filing. The repurchase authorization does not appear to be tied to a specific expiration date or maximum share count in the disclosed materials.

Announced a share repurchase program of up to $100 million, of which approximately $82.1 million remains available for repurchase under the existing Board authorization. — Caris Life Sciences, Inc. 8-K filing · View on SEC EDGAR →

What this means

Caris Life Sciences has authorized a $100 million buyback program under Board authorization, with $82.1 million currently available, implying that approximately $17.9 million has already been deployed. The company's strong operational momentum—evidenced by 45% revenue growth and a return to profitability in Q2—provides balance-sheet capacity for the repurchase. At current share count (approximately 282.6 million shares outstanding as of June 30, 2026), the $100 million authorization represents roughly 0.35% of market capitalization. The filing does not specify whether repurchases will be executed via open-market Rule 10b-18 purchases, accelerated share repurchase agreements, or 10b5-1 trading plans, nor does it disclose timing or acceleration mechanisms.

Frequently asked questions

How much of the $100 million authorization has already been used?: Approximately $17.9 million has been utilized under the program, leaving $82.1 million available for future repurchases. The filing does not break down the timing or execution of these prior repurchases.
What does Caris Life Sciences do with the shares it repurchases?: The filing does not explicitly state the intended use. Share repurchases typically reduce share count, potentially increasing earnings per share, and can return capital to remaining shareholders. Repurchased shares may also be held in treasury for other corporate purposes.
Does the filing specify how these shares will be repurchased?: No. The filing does not disclose whether repurchases will be executed as open-market purchases under Rule 10b-18, via an accelerated share repurchase (ASR) agreement, or through a 10b5-1 trading plan.
Why is Caris announcing a buyback now?: The company reported record Q2 results, including 45% revenue growth and positive free cash flow of $6.4 million for the quarter. Strong operational performance and positive cash generation provide the financial foundation to return capital to shareholders through repurchases.
How does this buyback compare to Caris's market capitalization?: The $100 million authorization represents approximately 0.35% of the company's market capitalization based on its ~282.6 million outstanding shares as of June 30, 2026. The relative size is modest compared to the company's total equity value.

authorization biotech taquitecture precision-medicine positive-fcf

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.